Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAR441169
- Development stage
- Discontinued
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SAR441169 is a small molecule drug developed as an inverse agonist of the nuclear hormone receptor RORγt (retinoic acid receptor-related orphan receptor gamma t). It was designed to modulate the interleukin-17 inflammatory pathway, which plays a critical role in chronic autoimmune diseases such as psoriasis. The drug was initially developed by Lead Pharma and later co-developed with Sanofi. Its primary indication was for the treatment of psoriasis, aiming to provide an oral alternative to injectable biologics targeting similar pathways. Clinical development reached Phase 1 trials but has since been discontinued for psoriasis[1][2][3][4].
- Other names
- Retinoid orphan receptor gamma t inhibitor
02
Targets
RORγtRORC (Retinoic acid receptor-related orphan receptor gamma)
Beyond the preview
Go deeper on SAR441169.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAR441169.